Macroalbuminuria and microalbuminuria: do both predict renal and cardiovascular events with similar strength?
Explore this paper's citation graph
Summary
Findings in microalbuminuria are especially of importance for the renal community, as screening for albuminuria is not carried out systematically even in patients with increased risk for micro Albuminuria, such as those with diabetes and those with essential hypertension.
- Type
- article
- Published
- 2007-07-01
- Cited by
- 45
- References
- 24
- OpenAlex
- https://openalex.org/W1788227665
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:28401502
Keywords
Microalbuminuria, Medicine, Albuminuria, Diabetes mellitus, Internal medicine
References
- Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension
- Albuminuria and Cardiovascular Risk in Hypertensive Patients with Left Ventricular Hypertrophy: The LIFE Study
- Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: a twenty-three year follow-up study.
- Proteinuria and the risk of developing end-stage renal disease.
- Microalbuminuria as predictor of increased mortality in elderly people.
- Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study
- Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
- The increased risk of coronary heart disease associated with nephrotic syndrome.
- Early detection of patients at risk of developing diabetic nephropathy. A longitudinal study of urinary albumin excretion.
- Retarding progression of chronic renal disease: the neglected issue of residual proteinuria.
- Progression of Chronic Kidney Disease: The Role of Blood Pressure Control, Proteinuria, and Angiotensin-Converting Enzyme Inhibition: A Patient-Level Meta-Analysis
- Clinical utility of trace proteinuria for microalbuminuria screening in the general population
- An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population.
- Urinary Albumin Excretion and the Risk of Graft Loss and Death in Proteinuric and Non‐proteinuric Renal Transplant Recipients
- Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.
- Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening.
- Renoprotective therapy: titration against urinary protein excretion.
- Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity
- Cost-effectiveness of screening for proteinuria.
- Screening for proteinuria in US adults: a cost-effectiveness analysis.
Cited by
- Microalbuminuria breakthrough under chronic renin–angiotensin–aldosterone system suppression
- Comparing Performances of Logistic Regression, Classification & Regression Trees and Artificial Neural Networks for Predicting Albuminuria in Type 2 Diabetes Mellitus
- Predictors of Albuminuria and Uncontrolled Blood Pressure in People with Hypertension in The Community
- Identification and Management of Albuminuria in the Primary Care Setting
- Renal Cannabinoid Receptor Expressionand Function: Their Role in Obesity andDiabetes
- The Comparisons of Four Splitting Rules for Fitting a Classification Tree with Simulation and an Application Related to Albuminuria Data in Type 2 Diabetes Mellitus
- Prediction of development and maintenance of high albuminuria during chronic renin-angiotensin suppression by plasma proteomics.
- Microalbuminuria as a risk factor: the influence of renin–angiotensin system blockade
- Renal function and target organ damage in hypertension.
- Evolución de la enfermedad cardiorrenal bajo la supresión crónica del sistema renina-angiotensina
- Monitoring and Managing Urinary Albumin Excretion: Practical Advice for Primary Care Clinicians
- Understanding the Mechanisms of Proteinuria: Therapeutic Implications
- High variability of albuminuria in nondiabetic population: the Takahata Study
- Effect of short-term high-protein compared with normal-protein diets on renal hemodynamics and associated variables in healthy young men.
- Focus on Microalbuminuria to Improve Cardiac and Renal Protection
- Switching to multiple daily injection therapy with glulisine improves glycaemic control, vascular damage and treatment satisfaction in basal insulin glargine‐injected diabetic patients
- Apolipoprotein B attenuates albuminuria-associated cardiovascular disease in prevention of renal and vascular endstage disease (PREVEND) participants.
- Test characteristics of urine dipstick for identifying renal insufficiency in patients with diabetes.
- Altered serum levels of FGF-23 and magnesium are independent risk factors for an increased albumin-to-creatinine ratio in type 2 diabetics with chronic kidney disease.
- Factors associated with impaired urinary albumin excretion in hypertensive individuals: albuminuria and hypertension.
Related papers
- Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.
- Albuminuria reflects widespread vascular damage
- Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity
- The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
- Cardiovascular risk in patients with diabetic kidney disease.
- The importance of microalbuminuria as a cardiovascular risk indicator: A review.
- Urinary Albumin Excretion Predicts Cardiovascular and Noncardiovascular Mortality in General Population
- Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
- Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
- Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.